Infusion of soluble myelin basic protein protects long term against induction of experimental autoimmune encephalomyelitis

Immunology and Cell Biology

Volumn 75, Issue 1, 1997, Pages 54-64

  Staykova, Maria A ^a   Simmons, Rex D ^a   Willenborg, David O ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

experimental autoimmune encephalomyelitis; myelin basic protein; tolerance

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; MYELIN BASIC PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSFER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; RAT; SPLEEN CELL;

ANIMALIA;

EID: 0031054723     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.9     Document Type: Article

References (50)

1. Swierkosz JE, Swanborg RH. Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis. J. Immunol. 1975; 115: 631-3.
2. Swierkosz JE, Swanborg RH. Characterization of suppressor cells involved in regulation of experimental allergic encephalomyelitis. Eur. J. Immunol. 1976; 6: 910-13.
3. Swierkosz JE, Swanborg RH. Immunoregulation of experimental allergic encephalomyelitis: Conditions for induction of suppressor cells and analysis of mechanism. J. Immunol. 1977; 119: 1501-6.
4. Driscoll BF, Kies MW, Alvord EC. Protection against experimental allergic encephalomyelitis with peptides derived from myelin basic protein: Presence of intact encephalitogenic site is essential. J. Immunol. 1976; 17: 110-14.
5. Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992; 258: 1491-4.
6. Bitar DM, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell. Immunol. 1988; 112: 364-70.
7. Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 1988; 140: 440-5.
8. Friedman A, Al-Sabbagh A, Santos LMB et al. Oral tolerance: A biologically relevant pathway to generate peripheral tolerance against external and self antigens. In: Granstein RD. (ed). Mechanisms of Immune Regulation. Chem. Immunol. Basel: Karger. 1994; 259-90.
9. Levine S, Sowinski R, Kies MW. Treatment of experimental allergic encephalomyelitis with encephalitogenic basic protein. Proc. Soc. Exp. Biol. Med. 1972; 139: 506-10.
10. Willenborg DO, Staten EA, Witting GF. Experimental allergic encephalomyelitis: Modulation by intraventricular injection of myelin basic protein. Exp. Neurol. 1978; 61: 527-32.
11. Critchficld JM, Racke MK, Zuniga-Ptlucker JC et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263: 1139-43.
12. Kennedy MK, Dal Canto MC, Trotter JL, Miller SD. Specific immune regulation of chronic-relapsing experimental allergic encephalomyelitis in mice. J. Immunol. 1988; 141: 2986-93.
13. Kennedy MK, Tan LJ, Dal Canto MC et al. Inhibition of murine relapsing experimental allergic encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 1990; 144: 909-15.
14. Pope L, Paterson PY, Miller SD. Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 1992; 37: 177-90.
15. Santambrogio L, Crisi GM, Leu J, Hochwald GM, Ryan T, Thorbccke GJ. Tolerogenic forms of auto-antigens and cytokines in the induction of experimental allergic encephalomyelitis. J. Neuroimmunol. 1995; 58: 211-22.
16. Hugh AR, Simmons RD, Willenborg DO. Immediate, long-lasting suppression of autoimmune encephalomyelitis by cell-bound neuroantigen. Cell. Immunol. 1989; 123: 108-17.
17. Willenborg DO, Staykova MA, Miyasaka M. Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: Treatment abrogates autoimmune disease but not autoimmunity. J. Immunol. (in press).
18. Eylar EH, Kniskern PJ, Jackson JJ. Myelin basic proteins. In: Fleischer S, Packer L, (eds). Methods in Enzymology. New York: Academic Press. 1974; 323-41.
19. Willenborg DO, Fordham SA, Cowden WB, Ramshaw IA. Cytokines and murine autoimmune encephalomyelitis: Inhibition or enhancement of disease with antibodies to select cytokines or by delivery of exogenous cytokines using a recombinant Vaccinia virus system. Scand. J. Immunol. 1995; 41: 31-41.
20. Panitch HS, McFarlin DE. Experimental allergic encephalomyelitis: Enhancement of cell-mediated transfer by concanavalin A. J. Immunol. 1977; 119: 1134-7.
21. + T lymphocytes. J. Immunol. 1989; 142: 748-52.
22. Jacobs MJM, van den Hock AEM, van de Putta LBA, van den Berg WB. Suppression of hen egg lysozyme-induced arthritis by intravenous antigen administration: No role in this for antigen-driven bystander suppression. Clin. Exp. Immunol. 1994; 96: 36-42.
23. Miller A, Zhang ZJ, Sobel RA, Al-Sabbagh A, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI Suppression of adoptively transferred disease and different effects of oral versus intravenous tolerization. J. Neuroimmunol. 1993; 46: 73-82.
24. Simon J, Nowoczek G. Protective effect of competitive target structure on experimental allergic encephalomyelitis. J. Neurol. Sci. 1978; 38: 383-9.
25. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transform ing growth factor-β after antigen-triggering. Proc. Natl Acad. Sci. USA 1992; 89: 421-5.
26. Santos LMB, Al-Sabbagh A, Londono A, Weiner HL. Oral tolerance to myelin basic protein induces TGF-β secreting cells in Peyer's patches. J. Immunol. 1993; 150: 115-19.
27. van Laar JM, Miltenburg AMM, Breedveld FC, Cohen IR, de Vries RRP. Toward T cell vaccination in rhematoid arthritis. In: Granstein RD, (ed). Mechanisms of Immune Regulation. Basel: Karger. 1994; 206-235.
28. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J. Immunol. 1991; 147: 2155-63.
29. Movat Mc IA, Strobel S, Drumond HE, Ferguson A. Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunology. 1982; 45: 105-13.
30. + regulatory T cells. Clin. Immunol. Immunopath. 1992; 62: 210-19.
31. Staykova M, Goranov I, Nikolov T. L' influence du cyclophosphamide sur le development de EAE. Ann. Inst. Pasteur/Immunol. 1979; 129: 415-27.
32. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-56.
33. + Th 1 but not Th2 cytokine responses. Intern. Immunol. 1994; 6: 721-30.
34. Friedman A, Weiner H. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl Acad. Sci. USA 1994; 91: 6688-92.
35. Critchfield JM, Racke MK, Zuniga-Pflucker JC et al. T cell deletion in high dose therapy of autoimmune encephalomyelitis. Science 1994; 263: 1139-43.
36. Parish CR. Immune deviation: A historical perspective. Immunol. Cell Biol. 1996; 74: 449-56.
37. Charlton B, Lafferty KJ. The Thl/Th2 balance in autoimmunity. Curr. Opin. Immunol. 1996; 7: 793-8.
38. Wekerle H. Myelin specific, autoaggressive T cell clones in the normal immune repertoir: Their nature and their regulation. Intern. Rev. Immunol. 1992; 9: 231-41.
39. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA. Surface expression of a4-integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 1993; 177: 57-68.
40. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steiman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-6.
41. van der Veen RC, Kapp JA, Trotter JL. Fine specificity differences in the recognition of an encephalitogenic peptide by T helper 1 and 2 cells. J. Neuroimmunol. 1993; 48: 221-6.
42. + T cell clones in the rat. Cloning methodology and IFNg secretion. J. Immunol. Meth. 1989; 121: 185-96.
43. Pcrnis A, Gupta S, Gollob KJ et al. Lack of interferon gamma receptor beta chain and the prevention of interferon gamma signaling in Th 1 cells. Science 1995; 269: 245-7.
44. Finkelman FD, Holmes J, Katona IM et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 1990; 8: 303-33.
45. Burstein HJ, Abbas AK. In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J. Exp. Med. 1993; 177: 457-63.
46. Noble A, Kemeny DM. Interleukin-4 enhances interferon-g synthesis but inhibits development of interferon-γ-producing cells. Immunology 1995; 85: 357-63.
47. Perez VL, Lederer JAH, Abbas AK. Stability of Th 1 and Th2 populations. Intern. Immunol. 1995; 7: 869-75.
48. + T cells. Annu. Rev. Immunol. 1994; 12: 635-73.
49. Willenborg DO. Mechanisms of recovery and acquired resistance in Lewis rat experimental allergic encephalomyelitis. AJEBAK 1981; 59: 125-34.
50. MacPhee IAM, Day MJ, Mason DW. The role of serum factors in the suppression of experimental allergic encephalomyelitis: Evidence for immunoregulation by antibody to the encephalitogenic peptide. Immunology 1990; 70: 527-34.